title: Reply: Is Extended Sedation Necessary for Young Children Receiving High-Dose (131) I-MIBG Therapy?
authors.affiliation: Division of Hematology/Oncology, Department of Pediatrics, University of California, San Francisco, California.
authors.forename: Jean S
authors.initials: JS
authors.lastname: Lee
authors.affiliation: Division of Hematology/Oncology, Department of Pediatrics, University of California, San Francisco, California.
authors.forename: Katherine
authors.initials: K
authors.lastname: Matthay
authors.affiliation: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts.
authors.forename: Steven G
authors.initials: SG
authors.lastname: DuBois
authors.affiliation: Division of Critical Care, Department of Pediatrics, University of California, San Francisco, California.
authors.forename: Arup
authors.initials: A
authors.lastname: Roy-Burman
mesh_terms: D019797:3-Iodobenzylguanidine; D002648:Child; D006801:Humans; D007457:Iodine Radioisotopes; D009447:Neuroblastoma
chemical_list: D007457:Iodine Radioisotopes; D019797:3-Iodobenzylguanidine